Teesuvac Aps

Teesuvac Aps specializes in the TeesuVac Breast Biopsy Device Mark 1, which is specifically designed for breast tissue sampling and biopsy procedures. This device is intended for use in clinical settings where precise tissue extraction is required for diagnostic purposes.

Teesuvac Aps is headquartered in the United States. The company’s location ensures it operates within the regulatory framework of the FDA, which governs medical device authorization in the country.

The TeesuVac Breast Biopsy Device Mark 1 falls under Class II classification, which typically means it poses moderate risks and requires special controls to ensure safety and effectiveness. This classification is determined by regulatory authorities based on factors like the device’s intended use, potential risks, and clinical benefits.

The TeesuVac Breast Biopsy Device Mark 1 is listed in the FDA’s 510(k) registry, which tracks devices that have undergone a premarket notification process to demonstrate substantial equivalence to a legally marketed predicate device. This registry helps healthcare providers and regulators verify the device’s compliance and authorization status.

The Class II designation for the TeesuVac Breast Biopsy Device Mark 1 is based on its role in invasive procedures where precision and safety are critical. Such devices often require performance standards, labeling requirements, or post-market surveillance to mitigate risks like tissue damage, infection, or improper sampling. The classification ensures additional scrutiny to validate the device’s safety and efficacy before patient use.